Survival Rates for Ewing Tumors

Survival rates can give you an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time (usually 5 years) after they were diagnosed. They can’t tell you how long a person will live, but they may help give you a better understanding of how likely it is that treatment will be successful.

Keep in mind that survival rates are estimates and are often based on previous outcomes of large numbers of people who had a specific cancer, but they can’t predict what will happen in any particular person’s case. These statistics can be confusing and may lead you to have more questions. Talk with your doctor about how these numbers may apply to you (or your child), as he or she is familiar with your situation.

What is a 5-year relative survival rate?

A relative survival rate compares people with the same type and stage of cancer to people in the overall population. For example, if the 5-year relative survival rate for a specific stage of Ewing tumor is 80%, it means that people who have that cancer are, on average, about 80% as likely as people who don’t have that cancer to live for at least 5 years after being diagnosed.

Where do these numbers come from?

The American Cancer Society relies on information from the SEER* database, maintained by the National Cancer Institute (NCI), to provide survival statistics for different types of cancer.

The SEER database tracks 5-year relative survival rates for Ewing tumors in the United States, based on how far the cancer has spread. The SEER database, however, does not group cancers by AJCC TNM stages (stage 1, stage 2, stage 3, etc.). Instead, it groups cancers into localized, regional, and distant stages:

  • Localized: There is no sign that the cancer has spread outside of the bone (or other area) where it started.
  • Regional: The cancer has spread outside the bone (or other area) and into nearby structures, or it has reached nearby lymph nodes.
  • Distant: The cancer has spread to distant parts of the body, such as to the lungs or to bones in other parts of the body.

5-year relative survival rates for Ewing tumors

(Based on people diagnosed with Ewing tumors between 2008 and 2014.)

SEER stage

5-year relative survival rate

Localized

83%

Regional

69%

Distant

37%

All SEER stages combined

62%

 

Understanding the numbers

  • These numbers apply only to the stage of the cancer when it is first diagnosed. They do not apply later on if the cancer grows, spreads, or comes back after treatment.
  • These numbers don’t take everything into account. Survival rates are grouped based on how far the cancer has spread. But other factors, such as those listed below, can also affect a person’s outlook.
  • People now being diagnosed with Ewing tumors may have a better outlook than these numbers show. Treatments improve over time, and these numbers are based on people who were diagnosed and treated at least 5 years earlier.

Other factors that can affect prognosis (outlook)

Factors other than the stage of the cancer can also affect survival rates. Factors that have been linked with a better prognosis include:

  • Smaller tumor size
  • Main tumor is on an arm or leg (as opposed to chest wall or pelvis)
  • Normal blood LDH level
  • Good tumor response to chemotherapy
  • Age younger than 10 years

Even when taking these other factors into account, survival rates are at best rough estimates. Your cancer care team is your best source of information on this topic.

*SEER = Surveillance, Epidemiology, and End Results

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Anderson ME, Randall RL, Springfield DS, Gebhart MC. Chapter 92: Sarcomas of bone. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa: Elsevier; 2014.

DeLaney TF, Hornicek FJ. Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors. UpToDate. Accessed at www.uptodate.com/contents/clinical-presentation-staging-and-prognostic-factors-of-the-ewing-sarcoma-family-of-tumors on March 5, 2018.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Bone Cancer. Version 1.2018. Accessed at www.nccn.org/professionals/physician_gls/pdf/bone.pdf on March 5, 2018.

Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.

Last Medical Review: May 31, 2018 Last Revised: March 1, 2019

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.